**Question:** Recombinant form of a hormone used in osteoporosis is

A. Parathyroid hormone (PTH)
B. Calcitonin
C. Estrogen
D. Bisphosphonates

**Correct Answer:** D. Bisphosphonates

**Core Concept:** Osteoporosis is a condition characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to an increased risk of fractures. Treatment options include medications that target different aspects of bone remodeling and structure.

**Why the Correct Answer is Right:** Bisphosphonates are a class of drugs that inhibit osteoclast-mediated bone resorption, thereby reducing bone loss and improving bone mineral density. They work by binding to hydroxyapatite in bone, preventing osteoclasts from attaching and functioning properly, leading to reduced bone resorption. This is particularly useful in osteoporosis, where bone loss is a significant concern.

**Why Each Wrong Option is Incorrect:**

A. Parathyroid hormone (PTH) is a hormone that increases bone resorption and calcium absorption from the intestines, making it an inappropriate choice for treating osteoporosis, which aims to reduce bone resorption and increase bone mass.

B. Calcitonin is a hormone that inhibits bone resorption, but it is derived from salmon pituitary glands and has limited bioavailability. Recombinant human calcitonin (e.g., salmon calcitonin) is an incorrect choice because it is not a recombinant form of a hormone specifically developed for the treatment of osteoporosis.

C. Estrogen is a hormone that increases bone mass and reduces bone resorption, but it is a sex hormone primarily affecting female reproductive system and is not specifically designed for the treatment of osteoporosis. Recombinant estrogen is an incorrect choice as well.

**Clinical Pearl:** Osteoporosis is a common problem among elderly individuals, particularly postmenopausal women. While some of the other options (PTH, calcitonin, estrogen) have roles in bone remodeling, bisphosphonates are the preferred choice due to their effectiveness, long-term benefits, and proven efficacy in reducing fracture risk in osteoporosis patients.